Subcutaneous hydrocortisone ( DrugBank: Hydrocortisone )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 81 | Congenital adrenal hyperplasia | 6 |
81. Congenital adrenal hyperplasia
Clinical trials : 88 / Drugs : 90 - (DrugBank : 23) / Drug target genes : 12 - Drug target pathways : 68
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03718234 (ClinicalTrials.gov) | January 1, 2019 | 11/10/2018 | Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia | Interval Bolus Delivery of Subcutaneous Hydrocortisone Via Infusion Pump in Children With Congenital Adrenal Hyperplasia | Congenital Adrenal Hyperplasia;Hyperplasia;Adrenal Hyperplasia;Congenital Disorders;Adrenocortical Hyperfunction;Disorders of Sex Development;Urogenital Abnormalities;Genetic Diseases, Inborn;Steroid Metabolic Diseases, Inborn;Adrenal Gland Disease;Hydrocortisone | Drug: Subcutaneous hydrocortisone;Drug: Standard glucocorticoid therapy | University of Minnesota | NULL | Recruiting | 4 Years | 18 Years | All | 8 | Phase 1 | United States |
| 2 | EUCTR2011-005822-23-SE (EUCTR) | 18/11/2014 | 20/09/2013 | A trial comparing continuous subcutaneous hydrocortisone infusion (CSHI) therapy with conventional oral glucocorticoid therapy in patients with Congenital Andrenal Hyperplasia (CAH) | CONTINUOUS SUBCUTANEOUS HYDROCORTISONE INFUSION IN CONGENITAL ADRENAL HYPERPLASIA | Congenital Adrenal Hyperplasia MedDRA version: 14.1;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Solu-Cortef INN or Proposed INN: HYDROCORTISONE SODIUM SUCCINATE Other descriptive name: HYDROCORTISONE SODIUM SUCCINATE INN or Proposed INN: Prednisolone INN or Proposed INN: Hydrocortisone | Haukeland University Hospital | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | Norway;Sweden | ||
| 3 | NCT02096510 (ClinicalTrials.gov) | August 2014 | 28/11/2013 | Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia | Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia | Addison Disease;Adrenal Hyperplasia Congenital | Drug: Solu-Cortef;Drug: Cortef | Haukeland University Hospital | NULL | Recruiting | 18 Years | 65 Years | Both | 10 | Phase 1/Phase 2 | Norway |
| 4 | NCT01859312 (ClinicalTrials.gov) | May 6, 2013 | 17/5/2013 | Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia | A Pilot Study Assessing the Use of Continuous Subcutaneous Hydrocortisone Infusion in the Treatment of Congenital Adrenal Hyperplasia | Adrenal Insufficiency;Excess Androgen;Congenital Adrenal Hyperplasia (CAH) | Drug: Hydrocortisone (Solucortef);Device: Insulin pump (Medtronic) | National Institutes of Health Clinical Center (CC) | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | 18 Years | 99 Years | All | 8 | Phase 2 | United States |
| 5 | NCT01771328 (ClinicalTrials.gov) | February 2013 | 10/1/2013 | Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia | Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia | Adrenal Hyperplasia, Congenital | Drug: Hydrocortisone;Drug: Cortisone acetate | Haukeland University Hospital | NULL | Recruiting | 18 Years | 60 Years | Both | 20 | Phase 2 | Norway |
| 6 | EUCTR2011-005822-23-NO (EUCTR) | 16/10/2012 | 25/02/2013 | A trial comparing continuous subcutaneous hydrocortisone therapy with conventional oral glucocorticoid therapy in congenital adrenal hyperplasia | CONTINUOUS SUBCUTANEOUS HYDROCORTISONE INFUSION IN CONGENITAL ADRENAL HYPERPLASIA | Congenital adrenal hyperplasia (CAH) MedDRA version: 14.1;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Solu-Cortef Trade Name: Cortison Trade Name: Prednisolone | Haukeland University Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Norway |